ASCL1 and small cell lung carcinoma: As NOTCH2 protein expression was observed to be higher in group 2 (TTF1 low), while ASCL1 was higher in group 1 (TTF1 high), we investigated whether the proteomically defined subsets would also delineate SCLC subsets with different expression of DLL3 and, therefore, vulnerability to rovalpituzumab tesirine.